Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

Yes, this last PR leaves it uncertain, Leo

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
steelyeye Member Profile
 
Followed By 47
Posts 4,025
Boards Moderated 0
Alias Born 03/04/12
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/9/2021 1:45:15 PM
IQST Has Catalysts On Deck That Expose A Valuation Disconnect of Roughly 100% - Here's Why That Gap Should Close InvestorsHub NewsWire - 11/5/2021 10:20:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/14/2021 5:01:12 PM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/11/2021 7:00:00 AM
CEO's Presenting on the Emerging Growth Conference 17 TODAY.  Register Now InvestorsHub NewsWire - 9/29/2021 8:00:00 AM
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth InvestorsHub NewsWire - 9/28/2021 7:24:31 AM
Nightfood, Inc. (OTCQB: NGTF) Significant Retail Expansion InvestorsHub NewsWire - 7/21/2021 6:47:54 AM
Innovation Pharma selected for a presentation on experimental COVID-19 therapy Seeking Alpha - 6/18/2021 10:31:54 AM
The Emerging Growth Conference is Today.  Register Now. InvestorsHub NewsWire - 6/9/2021 7:00:00 AM
Patient enrollment reaches 90 percent in Innovation Pharmaceuticals' mid-stage COVID-19 trial Seeking Alpha - 5/27/2021 10:29:46 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 8:01:45 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 5/3/2021 12:54:36 PM
Innovation gives update on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 4/5/2021 8:03:34 AM
CLS Holdings, (OTCQB: CLSH) $1.49 million Net Revenue for Feb Highest in Company History InvestorsHub NewsWire - 3/9/2021 6:37:33 AM
Innovation updates on mid-stage Brilacidin COVID-19 trial Seeking Alpha - 3/5/2021 1:07:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/22/2021 11:20:39 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/17/2021 8:01:12 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/11/2021 4:47:49 PM
CLS Holdings, (OTCQB: CLSH) Record January NET Revenue of $1.48 Million Beating Target InvestorsHub NewsWire - 2/9/2021 6:48:48 AM
CLS Holdings, (OTCQB: CLSH) $17 million Sales, 60% Growth & 5 New Products InvestorsHub NewsWire - 2/2/2021 6:52:54 AM
steelyeye   Tuesday, 10/12/21 08:17:02 PM
Re: Michel post# 378188
Post # of 387663 
Yes, this last PR leaves it uncertain, Leo could announce data lock or simply spring topline results without warning. Thanks, in either case we are very close!

"Based on information received from the data management and biostatistics vendors, study unblinding, analysis of the unblinded data and release of topline study results for the Brilacidin COVID-19 trial is anticipated to occur in mid-to-late October. The Company looks forward to the data to learn if Brilacidin’s multiple properties translate into meaningful clinical results, given the unmet need for COVID-19 therapeutics and ongoing pandemic."



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences